Patent Document ID: 8589175
Application ID: 12085606
Patent Flag: 1

Claim One:
1. A method for determining a starting dose of a neuropsychiatric drug for administration to a patient in need thereof, the method comprising: (a) receiving at a processor the usual drug dose for the population representing the patient (Dpop); (b) receiving at a processor the patient's genotype for a panel of genes comprising the following cytochrome P450 (CYP) genes: CYP2D6, CYP2C19, and CYP2C9; (c) determining the number of functional and non-functional alleles for each gene based on said genotype; (d) assigning the patient into a metabolizer phenotype subgroup based upon the number of functional alleles for each of the CYP genes wherein the metabolizer subgroup is selected from one of the following: Extensive metabolizer (EM)=2 functional alleles, Intermediate metabolizer (IM)=1 functional allele, and Poor metabolizer (PM)=0 functional alleles; (e) receiving at a processor the frequency of the metabolizer phenotype subgroups in the population; (f) determining, via a processor, the starting dose of the drug expressed as a percentage based on the number of non-functional alleles as follows: Percent reduction for one non-functional allele: (DREM %−DRIM %)/DREM % Percent reduction for two non-functional alleles: (DREM %−DRPM %)/DREM % wherein DRX % is the dosing recommendation for metabolizer subgroup X expressed as a percentage of the usual drug dose (Dpop), wherein DEM is reduced by 20% for every non-functional CYP2D6 or CYP2C19 allele and by 40% for every non-functional CYP2C9 allele, and (g) administering the starting dose of the drug determined in step (f) to the patient.